Platinum(IV) compounds as potential drugs: a quantitative structure-activity relationship study.

IF 2.2 4区 工程技术 Q3 PHARMACOLOGY & PHARMACY
Bioimpacts Pub Date : 2023-01-01 Epub Date: 2023-01-07 DOI:10.34172/bi.2023.24180
Jurica Novak, Alena R Zykova, Vladimir A Potemkin, Vladimir V Sharutin, Olga K Sharutina
{"title":"Platinum(IV) compounds as potential drugs: a quantitative structure-activity relationship study.","authors":"Jurica Novak,&nbsp;Alena R Zykova,&nbsp;Vladimir A Potemkin,&nbsp;Vladimir V Sharutin,&nbsp;Olga K Sharutina","doi":"10.34172/bi.2023.24180","DOIUrl":null,"url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Machine learning methods, coupled with a tremendous increase in computer power in recent years, are promising tools in modern drug design and drug repurposing.</p><p><strong>Methods: </strong>Machine learning predictive models, publicly available at chemosophia.com, were used to predict the bioactivity of recently synthesized platinum(IV) complexes against different kinds of diseases and medical conditions. Two novel QSAR models based on the BiS algorithm are developed and validated, capable to predict activities against the SARS-CoV virus and its RNA dependent RNA polymerase.</p><p><strong>Results: </strong>The internal predictive power of the QSAR models was tested by 10-fold cross-validation, giving cross-R<sup>2</sup> from 0.863 to 0.903. 38 different activities, ranging from antioxidant, antibacterial, and antiviral activities, to potential anti-inflammatory, anti-arrhythmic and anti-malarial activity were predicted for a series of eighteen platinum(IV) complexes.</p><p><strong>Conclusion: </strong>Complexes <b>1</b>, <b>3</b> and <b>13</b> have high generalized optimality criteria and are predicted as potential SARS-CoV RNA dependent RNA polymerase inhibitors.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/71/bi-13-373.PMC10509740.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioimpacts","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.34172/bi.2023.24180","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Machine learning methods, coupled with a tremendous increase in computer power in recent years, are promising tools in modern drug design and drug repurposing.

Methods: Machine learning predictive models, publicly available at chemosophia.com, were used to predict the bioactivity of recently synthesized platinum(IV) complexes against different kinds of diseases and medical conditions. Two novel QSAR models based on the BiS algorithm are developed and validated, capable to predict activities against the SARS-CoV virus and its RNA dependent RNA polymerase.

Results: The internal predictive power of the QSAR models was tested by 10-fold cross-validation, giving cross-R2 from 0.863 to 0.903. 38 different activities, ranging from antioxidant, antibacterial, and antiviral activities, to potential anti-inflammatory, anti-arrhythmic and anti-malarial activity were predicted for a series of eighteen platinum(IV) complexes.

Conclusion: Complexes 1, 3 and 13 have high generalized optimality criteria and are predicted as potential SARS-CoV RNA dependent RNA polymerase inhibitors.

Abstract Image

Abstract Image

Abstract Image

铂(IV)化合物作为潜在药物:定量构效关系研究。
引言:机器学习方法,加上近年来计算机能力的巨大增长,是现代药物设计和药物再利用的有前途的工具。方法:使用可在chemophia.com上公开的机器学习预测模型来预测最近合成的铂(IV)配合物对不同疾病和医疗条件的生物活性。开发并验证了两个基于BiS算法的新型QSAR模型,它们能够预测针对严重急性呼吸系统综合征冠状病毒及其RNA依赖性RNA聚合酶的活性。结果:通过10倍交叉验证检验了QSAR模型的内部预测能力,得出的交叉R2为0.863至0.903。预测了一系列18种铂(IV)复合物的38种不同活性,从抗氧化、抗菌和抗病毒活性,到潜在的抗炎、抗心律失常和抗疟疾活性。结论:配合物1、3和13具有较高的广义最优性标准,被预测为潜在的严重急性呼吸系统综合征冠状病毒RNA依赖性RNA聚合酶抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioimpacts
Bioimpacts Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
4.80
自引率
7.70%
发文量
36
审稿时长
5 weeks
期刊介绍: BioImpacts (BI) is a peer-reviewed multidisciplinary international journal, covering original research articles, reviews, commentaries, hypotheses, methodologies, and visions/reflections dealing with all aspects of biological and biomedical researches at molecular, cellular, functional and translational dimensions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信